Logo
x

Search

Subscribe Now

 Clinical Trial

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic P...

  • November 21, 2024
Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeting

Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...

  • November 20, 2024
Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

  • November 20, 2024
GSK Reports the P-III (GLISTEN) Study Results of Linerixibat to Treat Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus

GSK Reports the P-III (GLISTEN) Study Results of Linerixibat to Treat Primary Biliary Cholangitis (PBC) Patients with Cholestatic...

  • November 19, 2024
Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events

Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events

  • November 19, 2024
EnteroBiotix Concludes Recruitment for P-II Trial of EBX-102-02 in IBS

EnteroBiotix Concludes Recruitment for P-II Trial of EBX-102-02 in IBS

  • November 18, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.